Cardiome Pharma ( CRME), a maker of heart drugs, saw its shares fall early Thursday after the company announced plans for a public offering of 8 million shares in the U.S. and Canada.

The stock lost 2.8% to $10.60 in premarket trading.

The company said late Wednesday that it will grant the underwriters an option to purchase an additional 1.2 million shares within 30 days after the offering closes to cover any overallotments.

Bear Stearns, CIBC World Markets, Canaccord Adams and Leerink Swann are managing the offering.